Table 1.
List of European Medicines Agency (EMA)-approved DPP4 inhibitors.
| Brand Name | Active Ingredient(s) | Marketing-Authorization Holder | EMA Product Number | EMA Approval Date 1 |
|---|---|---|---|---|
| Vipidia | Alogliptin | Takeda Pharma A/S (Vallensbæk Strand, Denmark) | EMEA/H/C/002182 | 18/09/2013 |
| Vipdomet | Alogliptin and metformin | Takeda Pharma A/S | EMEA/H/C/002654 | 18/09/2013 |
| Incresync | Alogliptin and pioglitazone | Takeda Pharma A/S | EMEA/H/C/002178 | 19/09/2013 |
| Trajenta | Linagliptin | Boehringer Ingelheim GmbH (Ingelheim and Rhein, Germany) | EMEA/H/C/002110 | 23/08/2011 |
| Jentadueto | Linagliptin and metformin | Boehringer Ingelheim GmbH | EMEA/H/C/002279 | 19/07/2012 |
| Glyxambi | Linagliptin and empagliflozin | Boehringer Ingelheim GmbH | EMEA/H/C/003833 | 11/11/2016 |
| Onglyza | Saxagliptin | AstraZeneca AB (Stockholm, Sweden) | EMEA/H/C/001039 | 30/09/2009 |
| Komboglyze | Saxagliptin and metformin | AstraZeneca AB | EMEA/H/C/002059 | 24/11/2011 |
| Qtern | Saxagliptin and dapagliflozin | AstraZeneca AB | EMEA/H/C/004057 | 15/07/2016 |
| Januvia | Sitagliptin | Merck Sharp & Dohme B.V. (Haarlem, Netherlands) | EMEA/H/C/000722 | 20/03/2007 |
| Xelevia | Sitagliptin | Merck Sharp & Dohme B.V. | EMEA/H/C/000762 | 21/03/2007 |
| Tesavel | Sitagliptin | Merck Sharp & Dohme B.V. | EMEA/H/C/000910 | 10/01/2008 |
| Efficib | Sitagliptin and metformin | Merck Sharp & Dohme B.V. | EMEA/H/C/000896 | 15/07/2008 |
| Janumet | Sitagliptin and metformin | Merck Sharp & Dohme B.V. | EMEA/H/C/000861 | 16/07/2008 |
| Velmetia | Sitagliptin and metformin | Merck Sharp & Dohme B.V. | EMEA/H/C/000862 | 16/07/2008 |
| Ristfor | Sitagliptin and metformin | Merck Sharp & Dohme B.V. | EMEA/H/C/001235 | 15/03/2010 |
| Ristaben | Sitagliptin | Merck Sharp & Dohme B.V. | EMEA/H/C/001234 | 15/03/2010 |
| Steglujan | Sitagliptin and ertuglifozin | Merck Sharp & Dohme B.V. | EMEA/H/C/004313 | 23/03/2018 (AM) |
| Galvus | Vildagliptin | Novartis Europharm Limited (Camberly, United Kingdom) | EMEA/H/C/000771 | 25/09/2007 |
| Eucreas | Vildagliptin and metformin | Novartis Europharm Limited | EMEA/H/C/000807 | 14/11/2007 |
| Xiliarx | Vildagliptin | Novartis Europharm Limited | EMEA/H/C/001051 | 19/11/2008 |
| Jalra | Vildagliptin | Novartis Europharm Limited | EMEA/H/C/001048 | 19/11/2008 |
| Zomarist | Vildagliptin and metformin | Novartis Europharm Limited | EMEA/H/C/001049 | 30/11/2008 |
| Icandra 2 | Vildagliptin and metformin | Novartis Europharm Limited | EMEA/H/C/001050 | 30/11/2008 |
1 Date (day/ month/year) of issue of marketing authorization valid throughout the European Union. 2 Previously vildagliptin/metformin hydrochloride Novartis. AM, additional monitoring. It means that this drug has more intense surveillance than other medicines.